ALB and melanoma: To directly test whether albumin differentially affects KIs including dabrafenib and encorafenib, we treated A375 melanoma cells with a KI dose response for 2 hours in the presence or absence of physiologic levels of HSA and measured downstream p-ERK1/2 levels by immunofluorescence (Fig. 6E).